Related references
Note: Only part of the references are listed.Novel antiplatelet agents in acute coronary syndrome
Francesco Franchi et al.
NATURE REVIEWS CARDIOLOGY (2015)
Stent thrombosis in a patient with high on-treatment platelet reactivity despite ticagrelor treatment
Anees Musallam et al.
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2015)
Heart Disease and Stroke Statistics-2014 Update A Report From the American Heart Association
Alan S. Go et al.
CIRCULATION (2014)
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention
Daniel Aradi et al.
EUROPEAN HEART JOURNAL (2014)
The Influence of Genetic Polymorphism of Cyp2c19 Isoenzyme on the Pharmacokinetics of Clopidogrel and Its Metabolites in Patients With Cardiovascular Diseases
Marta Karazniewicz-Lada et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes
Sahar Ismail et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2014)
Ideal Antiplatelet Therapy for Coronary Artery Disease: Focus on Adenosine Diphosphate Receptor Inhibitors
Suraj Chandrasekar et al.
AMERICAN JOURNAL OF THERAPEUTICS (2013)
Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial
P. Gabriel Steg et al.
CIRCULATION (2013)
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Jeffrey L. Anderson et al.
CIRCULATION (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Response Variability to P2Y12 Receptor Inhibitors Expectations and Reality
Jolanta M. Siller-Matula et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2013)
Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding
Udaya S. Tantry et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study
Gregg W. Stone et al.
LANCET (2013)
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
Philippe Gabriel Steg et al.
LANCET (2013)
Novel antiplatelet drugs in clinical development
Martin Ungerer et al.
THROMBOSIS AND HAEMOSTASIS (2013)
The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven
Vamsi Krishna et al.
CIRCULATION (2012)
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study
Deepak L. Bhatt et al.
EUROPEAN HEART JOURNAL (2012)
Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization The TRILOGY ACS Platelet Function Substudy
Paul A. Gurbel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
Matthew T. Roe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting
Jean-Philippe Collet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Emerging Antiplatelet Therapy for Coronary Artery Disease and Acute Coronary Syndrome
Kathleen A. Packard et al.
PHARMACOTHERAPY (2012)
Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial
Matthew J. Price et al.
CIRCULATION (2011)
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention The GRAVITAS Randomized Trial
Matthew J. Price et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis
Michael V. Holmes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention A Collaborative Meta-Analysis of Individual Participant Data
Somjot S. Brar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis
Daniel Aradi et al.
AMERICAN HEART JOURNAL (2010)
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies The RESPOND Study
Paul A. Gurbel et al.
CIRCULATION (2010)
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
Renli Teng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration A Systematic Meta-Analysis
Jean-Sebastien Hulot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin et al.
LANCET (2010)
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Guillaume Pare et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of resistance
Victor Serebruany et al.
AMERICAN HEART JOURNAL (2009)
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial
Matthew J. Price et al.
AMERICAN HEART JOURNAL (2009)
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis
Laurent Bonello et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Matthew J. Price
CIRCULATION (2009)
Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay A 12-Month Follow-Up
Rossella Marcucci et al.
CIRCULATION (2009)
Intravenous Platelet Blockade with Cangrelor during PCI.
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Platelet Inhibition with Cangrelor in Patients Undergoing PCI.
Robert A. Harrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
Matthew J. Price et al.
EUROPEAN HEART JOURNAL (2008)
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention - Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
Giuseppe Patti et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
Stephen D. Wiviott et al.
LANCET (2008)
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future
Nina C. Raju et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clopidogrel non responsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
Jaapjan D. Snoep et al.
AMERICAN HEART JOURNAL (2007)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
T Cuisset et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
ZM Chen et al.
LANCET (2005)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - A randomized controlled trial
SR Steinhubl et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Individual variations of platelet inhibition after loading doses of clopidogrel
P Järemo et al.
JOURNAL OF INTERNAL MEDICINE (2002)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
SR Mehta et al.
LANCET (2001)
Share Paper
